Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells.
From Promise to Therapy
Join The Seattle Genetics Team
We are a group of passionate innovators dedicated to positively impacting the lives of those living with cancer, and we're always looking to add to our team.
Seattle Genetics and Bristol-Myers Squibb Highlight Interim Results from Phase 1/2 Study Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed or Refractory Hodgkin Lymphoma More
Seattle Genetics Highlights Five-Year Survival Results from Phase 1 Trial of ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-Cell Lymphoma at ASH Annual Meeting More
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma More
Seattle Genetics At A Glance
|Global Headquarters||Bothell, WA|
|Number of Employees||1,000+|
|Clinical & preclinical pipeline programs||12+|
|ADCs in clinical trials using our technology||20+|
Tune in to hear from ECHELON-1 trial investigators and to hear SGEN mgmt discuss our other pipeline programs cards.twitter.com/cards/18ce53wd… · 6 days ago